Table 2 Details of the ASCT and hematopoietic engraftment (BenMel: Bendamustine/melphalan).

From: Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial

Parameters

Total cohort (n = 120)

Mel (n = 60)

BenMel (n = 60)

P value

CD34 + cells transplanted, ×106/ kg, median (range)

3.7 (2–7.8)

3.58 (2.1–7.2)

3.67 (2.3–7.7)

0.715

Interval to engraftment, days, median (range)

 Neutrophils >0.5 × 109/L

11 (10–60)

12 (10–18)

11 (10–60)

0.096

 Neutrophils >1.0 × 109/L

12 (10–60)

12 (10–35)

11 (10–60)

0.847

 Lymphocytes >0.5 × 109/L

13 (9–60)

13 (10–53)

13 (9–60)

0.992

 Lymphocytes >1.0 × 109/L

23 (10–143)

25 (10–60)

20 (11–143)

0.109

 Platelets >20 × 109/L

12 (9–47)

13 (9–47)

13 (9–30)

0.367

 Platelets >50 × 109/L

18 (9–60)

17 (12–53)

19 (9–60)

0.412

 Platelets >100 × 109/L

27 (9–102)

27 (14–102)

26 (9–65)

0.937

  1. Time to neutrophil engraftment was defined as the duration between day 0 and the first 3 days of neutrophils >0.5 × 109/L after ASCT. Time to platelet engraftment was defined as the duration between day 0 and the first day of platelets >20 × 109/L after ASCT (without previous platelet transfusion).
Back to article page